Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Antithrombotic therapy in the treatment of STEMI and NSTEMI patients (CROSBI ID 230514)

Prilog u časopisu | ostalo

Nikolić Heitzler, Vjeran ; Pavlov, Marin: Babić, Zdravko ; Bulj, Nikola Antithrombotic therapy in the treatment of STEMI and NSTEMI patients // Acta medica Croatica, 63 (2009), 1; 117-119

Podaci o odgovornosti

Nikolić Heitzler, Vjeran ; Pavlov, Marin: Babić, Zdravko ; Bulj, Nikola

engleski

Antithrombotic therapy in the treatment of STEMI and NSTEMI patients

By establishing the Croatian network of primary PCI more patients can now be treated by this method every year. Nevertheless, therapeutic success depends on appropriate, i.e. complete antithrombotic therapy. On the other hand, about half of inhabitants of Croatia have not yet been covered with primary PCI network. Aspirin has an established role in antithrombotic therapy, demonstrated in numerous clinical studies. Thienopirydines, especially clopidogrel, have improved the outcome of interventional cardiology. GP IIb/IIIa receptor inhibitors, despite their high price, pave their way into our daily practice. Heparin is an essential part of therapy for almost all acute coronary syndrome scenarios, but the role of low-molecular heparins is yet to be clarified. Fibrinolytic therapy still "saves lifes". By improving new fibrinolytics, they have become easier to use, entail less side effects and are more efficient.

acute myocardian infarction ; antithrombotic therapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

63 (1)

2009.

117-119

objavljeno

1330-0164

Povezanost rada

nije evidentirano

Indeksiranost